Core Viewpoint - China Health Technology Group (01069) has completed the placement agreement, with the placement of 17 million shares at a price of HKD 0.28 per share, representing approximately 16.52% of the company's enlarged issued share capital post-placement [1] Summary by Relevant Sections - **Placement Completion**: The placement has been finalized as of August 1, 2025, with all conditions of the placement agreement met [1] - **Share Details**: A total of 17 million shares were issued to no less than six subscribers under the terms of the placement agreement [1] - **Capital Impact**: The issuance of shares will increase the company's issued share capital by approximately 16.52% following the completion of the placement [1]

Group 1 - The core point of the article is that China Health Technology Group (01069.HK) has completed a placement agreement, issuing a total of 17 million shares at a price of HKD 0.28 per share, which represents approximately 16.52% of the company's enlarged issued share capital post-placement [1] - The net proceeds from the placement amount to approximately HKD 4.63 million [1] - The company plans to use the net proceeds for various purposes, including approximately HKD 1.45 million for leasing expenses, approximately HKD 0.58 million for employee costs, and approximately HKD 2.6 million for professional fees [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) 01069 | 說明 | 普通股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/ ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約。 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股份代號：1069） 完成根據一般授權配售新股份 配售代理 昌利證券有限公司 茲提述本公司日期為二零二五年七月二十二日內容有關根據一般授權配售新股份 之公告（「該公告」）。除另有界定者外，本公告所用詞彙與該公告所界定者具有相 同涵義。 完成根據一般授權配售新股份 董事會欣然宣佈，配售協議的所有條件已獲達成，而配售事項已於二零二五年八 月一日完成。合共17,000,000股配售股份已根據配售協議之條款及條件按配售價每 股配售股份0.28港元配發及發行予不少於六名承配人，相當於緊隨完成後經配發 及發行配售股份擴大之本公司已發行股本約16.52%。據董事經作出一切合理查詢 1 後所深知、盡悉及確信，(i) 各承配人為獨立第三方；及(ii) 概無承配人於緊隨配售 事項完成後成為主要股東（ ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國健康科技集團控股有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 FF301 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01069 | 說明 | 普通股 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | | 已發行股份總數 | | | 上月底結存 | | | 859,242,204 | | | 0 | | 859,242,204 | | 增加 / 減少 (-) | | | -773,317,984 | | | 0 | | | | 本月底結存 | | | 85,924,220 | | | 0 | | 85,924 ...

Group 1 - Nanshan Aluminum International (02610.HK) expects a mid-term net profit of approximately $225 million to $265 million for the six months ending June 30, 2025, compared to a net profit of about $159 million for the same period ending June 30, 2024 [1] - The increase in net profit is primarily attributed to an improvement in gross margin, driven by higher alumina prices and relatively stable unit production costs [1] - The average selling price of the company's products for the first half of 2025 is expected to be around $530 per ton, up from approximately $387 per ton in the first half of 2024, but lower than $561 per ton in the second half of 2024 [1] Group 2 - TCL Electronics (01070.HK) anticipates a year-on-year adjusted net profit growth of approximately 45% to 65% for the first half of 2025 [2] - Renrui Talent (06919.HK) expects a mid-term profit attributable to equity holders to increase by 66.7% to 94.1% [2] - China Rare Earth Holdings (03788.HK) reports an increase in total gold resources to 5.07 million ounces [2]

Core Viewpoint - The Hong Kong Stock Exchange has imposed disciplinary actions against two former directors of China Health Technology Group Holdings Limited for failing to fulfill their duties and not cooperating with the investigation regarding company lending activities and the sale of subsidiaries [1][2]. Group 1: Disciplinary Actions - The Hong Kong Stock Exchange declared that former executive director Wang Yue and former independent non-executive director Tian Guangmei are unsuitable to hold any director or senior management positions in the company or its subsidiaries [1]. - The disciplinary actions stem from their involvement in company lending activities from 2015 to 2019 and the sale of subsidiaries in 2018, where they did not fulfill their director responsibilities [1][2]. Group 2: Investigation Findings - Evidence revealed that Wang, responsible for the company's lending operations, approved loans totaling HKD 138.3 million without adequate due diligence, risk analysis, or credit assessment [2]. - It was found that some lenders were Wang's family members, and there was no evidence that he disclosed this information [2]. - The company recorded an approximately 86% impairment on receivables related to these loans in its 2019 annual results [2]. Group 3: Sale of Subsidiaries - In 2018, Wang and Tian facilitated the postponement of a payment of RMB 93 million from the buyer without guarantees or interest, which ultimately led to a full impairment of this amount in the company's 2019 results [2]. - There was no evidence that either Wang or Tian conducted any due diligence or credit assessment on the buyer prior to the sale [2]. - After resigning from their director positions, both individuals failed to respond to the Stock Exchange's investigation and reminder letters [2].

Revenue and Profitability - For the six months ended December 31, 2024, the company recorded revenue of approximately RMB 31,100,000, an increase from RMB 19,000,000 in the previous period, representing a growth of 63.16%[15] - The company generated timber sales revenue of approximately RMB 11,560,000 from the sale of 8,547 cubic meters of timber during the reporting period[9] - Ginseng business revenue amounted to approximately RMB 16,150,000, which includes RMB 10,770,000 from purchased ginseng and RMB 5,380,000 from self-cultivated ginseng[11] - The health products segment recorded revenue of approximately RMB 3,400,000 during the reporting period[12] - The gross profit for the reporting period was approximately RMB 2,800,000, down from RMB 3,800,000 in the previous period, indicating a decline of 26.32%[16] - The company recorded a profit of approximately RMB 5,000,000 during the reporting period, a significant decline from approximately RMB 201,400,000 in the previous period[21] - Revenue for the six months ended December 31, 2024, was RMB 31,112,000, an increase of 63.5% compared to RMB 19,020,000 for the same period in 2023[51] - Gross profit for the same period was RMB 2,777,000, down 26.2% from RMB 3,758,000 in 2023[51] - The company reported a profit before tax of RMB 5,042,000, significantly lower than RMB 201,423,000 in the previous year, primarily due to a one-time debt restructuring gain in 2023[51] - Net profit for the period was RMB 4,978,000, compared to RMB 201,421,000 in the prior year[51] - Total comprehensive income for the period was RMB 6,353,000, down from RMB 207,869,000 in 2023[51] Assets and Liabilities - As of December 31, 2024, the total assets of the group were approximately RMB 191,100,000, with net assets of approximately RMB 24,900,000 and cash and bank balances of approximately RMB 2,700,000[22] - The capital debt ratio as of December 31, 2024, was approximately 87.0%, down from 92.7% on June 30, 2024[26] - The total number of issued ordinary shares as of December 31, 2024, was 859,242,204 shares, an increase from 716,242,204 shares on June 30, 2024[27] - Non-current assets as of December 31, 2024, totaled RMB 137,728,000, an increase from RMB 130,844,000 as of June 30, 2024[52] - Current assets increased to RMB 53,357,000 from RMB 47,322,000 as of June 30, 2024[52] - Current liabilities rose to RMB 53,356,000 from RMB 49,315,000 as of June 30, 2024[52] - The company's net asset value increased to RMB 24,869,000 from RMB 12,963,000 as of June 30, 2024[53] - Total assets increased to RMB 191,085,000 as of December 31, 2024, up from RMB 178,166,000 as of June 30, 2024[69] - Total liabilities rose to RMB 166,216,000, compared to RMB 165,203,000 in the previous period[71] Expenses and Costs - Sales and distribution expenses during the reporting period were RMB 148,000, a significant decrease from RMB 623,000 in the previous period, primarily due to advertising expenses[17] - Administrative expenses increased by 11.9% from approximately RMB 8,400,000 in the previous period to approximately RMB 9,400,000, mainly due to legal and professional fees as well as depreciation expenses[18] - Financing costs rose to RMB 1,300,000 during the reporting period, up from approximately RMB 100,000 in the previous period, due to interest on promissory notes[20] - Employee costs totaled RMB 1,528,000, a decrease from RMB 1,884,000 in the previous year[77] - The cost of harvested timber was RMB 11,564,000, down from RMB 15,262,000 in the previous year[77] Cash Flow and Financing - Operating cash flow for the six months ended December 31, 2024, was RMB 1,769,000, down from RMB 3,293,000 in the same period of 2023[55] - The total cash and cash equivalents at the end of the period were RMB 2,676,000, a decrease from RMB 3,230,000 at the beginning of the period[55] - The company’s financing activities generated a net cash inflow of RMB 3,831,000 during the period[55] - The company issued a total of RMB 120,000,000 in notes secured by land, with varying interest rates from 0% to 6% over five years[101] Shareholder Information - The company maintained a public float of no less than 25% of its issued shares as required by listing rules[48] - The total issued and paid-up ordinary shares increased to 859,242,000 shares, up from 716,242,000 shares, an increase of 19.9%[102] - No dividends were declared or proposed for the six months ended December 31, 2024, consistent with the previous period[80] Ginseng and Timber Operations - The company has obtained a logging permit for 2024, allowing for a total logging volume of 8,547 cubic meters, which is higher than the previous year's logging volume[13] - The company plans to reduce reliance on suppliers by cultivating its own aged ginseng stock, aiming for self-sufficiency in ginseng production[13] - The company has initiated the manufacturing and trading of health products since November 2024, with plans to expand its market presence in China[13] - The company successfully planted its first batch of Epimedium on its owned forest land in June 2024, which is expected to generate future revenue[14] - The company has signed a legally binding framework agreement with independent suppliers for ginseng cultivation, ensuring a stable supply of ginseng seeds and technical support for a period of 10 years[10] - The forestry business generated revenue of RMB 11,564,000, while the ginseng business contributed RMB 16,152,000, and health products generated RMB 3,396,000[68] Risk Management - The company has implemented extensive measures to monitor and mitigate risks related to climate change, pests, and natural disasters affecting timber growth[94] - The company faces risks related to fluctuations in timber prices and sales volumes, and management conducts regular industry trend analyses to align pricing structures with market conditions[95] Taxation - The company reported a tax expense of RMB 64,000 for the six months ended December 31, 2024, compared to RMB 2,000 for the same period in 2023, indicating a significant increase[78] - The effective tax rate for qualifying group entities in Hong Kong is 8.25% on the first HKD 2 million of taxable profits and 16.5% on profits above that threshold[79] - The company has not reported any taxable profits for the current and previous periods, resulting in no tax provisions in the consolidated financial statements[79] Other Financial Information - Other income for the reporting period was approximately RMB 13,100,000, compared to approximately RMB 4,700,000 in the previous period, with the increase mainly attributed to the net gain from the fair value change of artificial forest assets[19] - Other total income net amount was RMB 13,140,000, significantly up from RMB 4,726,000 in the previous year[72] - The company has not issued any diluted earnings per share due to the absence of potential dilutive ordinary shares during the reporting periods[83]

Financial Performance - The company's revenue for the six months ended December 31, 2024, was RMB 31,112,000, representing a 63.5% increase compared to RMB 19,020,000 for the same period in 2023[4] - Gross profit for the same period was RMB 2,777,000, down 26.2% from RMB 3,758,000 in the previous year[4] - The company reported a pre-tax profit of RMB 5,042,000, a significant decrease from RMB 201,423,000 in the prior period, largely due to a one-time debt restructuring gain in the previous year[4] - The net profit for the six months was RMB 4,978,000, compared to RMB 201,421,000 in the previous year[4] - Total comprehensive income for the period was RMB 6,353,000, down from RMB 207,869,000 in the same period last year[4] - The net profit for the six months ended December 31, 2024, was RMB 4,978,000, compared to RMB 201,421,000 for the same period in 2023, showing a significant decrease due to restructuring costs[19][24] - The company recorded a debt restructuring gain of approximately RMB 202,024,000 during the review period, significantly impacting the financial results[24] - The financing costs for the six months ended December 31, 2024, were RMB 1,337,000, a notable increase from RMB 51,000 in the previous period[22] - The company reported a profit of approximately RMB 5,000,000, a significant decrease from RMB 201,400,000 in the previous period[49] Assets and Liabilities - The company's non-current assets totaled RMB 137,728,000 as of December 31, 2024, an increase from RMB 130,844,000 as of June 30, 2024[5] - Current assets increased to RMB 53,357,000 from RMB 47,322,000 in the previous period[5] - The company's total liabilities were RMB 53,356,000, compared to RMB 49,315,000 in the previous period, indicating a rise in financial obligations[6] - The total assets as of December 31, 2024, amounted to RMB 191,085,000, up from RMB 178,166,000 as of June 30, 2024, reflecting a growth of 7.1%[20] - The total liabilities increased to RMB 171,826,000 from RMB 165,203,000, indicating a rise of 4.0%[20] - As of December 31, 2024, the company had total assets of approximately RMB 191,100,000 and net assets of approximately RMB 24,900,000[50] - The capital debt ratio was approximately 87.0%, improved from 92.7% as of June 30, 2024[54] Business Segments - The company is engaged in forestry management, ginseng cultivation and trade, and health product manufacturing, indicating a diversified business model[8] - The forestry business generated revenue of RMB 11,564,000, while the ginseng business contributed RMB 16,152,000, indicating strong performance in these segments[19] - The health products segment generated revenue of RMB 3,396,000, contributing positively to the overall performance[19] - The company achieved a total revenue of approximately RMB 11,560,000 from timber sales during the reporting period, with a total harvesting volume of 8,547 cubic meters[36] - Ginseng business revenue reached approximately RMB 16,150,000, which includes RMB 10,770,000 from purchased ginseng and RMB 5,380,000 from self-cultivated ginseng[39] - The health products segment generated revenue of approximately RMB 3,400,000 since its launch in November 2024[40] - The company has initiated a health product manufacturing and trading business, with plans to produce ginseng gift boxes using self-cultivated ginseng by the first half of 2025[40] - The company has secured a harvesting permit for 2024, allowing for the planned timber sales to continue[36] - The company has established a long-term supply framework agreement with suppliers to ensure a stable supply of ginseng for its trading business[39] Governance and Compliance - The company has adopted all provisions of the corporate governance code as per the listing rules, ensuring compliance throughout the reporting period[68] - The board confirmed that all directors adhered to the code of conduct for securities trading during the reporting period[69] - The company has not purchased any liability insurance for directors and executives against legal claims as of December 31, 2024[70] - The audit committee, consisting of three independent non-executive directors, focuses on compliance with accounting standards and legal regulations[71] - The unaudited interim financial statements have been reviewed by the audit committee during the reporting period[72] - The interim results announcement will be published on the Hong Kong Stock Exchange and the company's website, containing all required information[73] - The board includes both executive and independent non-executive directors, ensuring a diverse governance structure[75] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[19] - The company successfully planted its first batch of Epimedium on its owned forest land in June 2024, which is expected to generate revenue in the future[42]

Financial Performance - For the fiscal year ending June 30, 2024, the company's revenue was approximately RMB 47,600,000, compared to RMB 58,717,000 for the fiscal year ending June 30, 2023, representing a decrease of about 19%[1] - The profit attributable to the owners of the company for the fiscal year 2024 was approximately RMB 200,000,000, a significant recovery from a loss of RMB 10,800,000 in the fiscal year 2023[1] - The total comprehensive income attributable to the owners for the fiscal year 2024 was approximately RMB 204,000,000, compared to a total comprehensive loss of RMB 10,100,000 in the fiscal year 2023[1] - Basic earnings per share for fiscal year 2024 were RMB 29.79, a recovery from a loss of RMB 9.80 per share in fiscal year 2023[1] - The company reported a net profit of RMB 200,013 thousand for the year ended June 30, 2024, compared to a net loss of RMB 10,800 thousand for the year ended June 30, 2023[15] - In fiscal year 2024, the company recorded a profit of approximately RMB 200,000,000, compared to a loss of approximately RMB 10,800,000 in fiscal year 2023[53] - The total comprehensive income attributable to the owners of the company for fiscal year 2024 was approximately RMB 204,000,000, while the total comprehensive expense for fiscal year 2023 was approximately RMB 10,100,000[53] Revenue Breakdown - Total revenue for the group decreased to RMB 47,606 thousand in 2024 from RMB 58,717 thousand in 2023, representing a decline of approximately 19%[13] - Forestry business revenue increased to RMB 32,521 thousand in 2024 from RMB 25,603 thousand in 2023, a growth of about 27%[15] - The ginseng business generated total revenue of approximately RMB 15,100,000 in fiscal year 2024, including RMB 12,540,000 from purchased ginseng and RMB 2,560,000 from self-cultivated ginseng[43] - The forestry management business generated revenue of approximately RMB 32,500,000 from the sale of 16,260 cubic meters of timber in fiscal year 2024[41] Expenses and Costs - The gross profit for fiscal year 2024 was RMB 1,897,000, down from RMB 11,510,000 in fiscal year 2023, indicating a decline in profitability[3] - Administrative expenses increased by 11.8% to approximately RMB 21,500,000 in fiscal year 2024, up from RMB 19,200,000 in fiscal year 2023[48] - The total employee costs for the year were RMB 3,308,000, down from RMB 5,326,000 in the previous year, reflecting a reduction of 37.9%[27] - The company incurred costs of RMB 32,522,000 for harvested timber, an increase from RMB 25,603,000 in the previous year[27] - The depreciation expense for right-of-use assets was RMB 4,880,000, compared to RMB 2,509,000 in the previous year, indicating a significant increase[27] Assets and Liabilities - The company's capital-to-debt ratio improved to approximately 92.7% in fiscal year 2024, down from 325.2% in fiscal year 2023, a decrease of 232.5 percentage points[1] - Total assets increased to RMB 178,166 thousand in 2024 from RMB 140,643 thousand in 2023, reflecting a growth of approximately 27%[17] - Total liabilities decreased significantly to RMB 165,203 thousand in 2024 from RMB 457,351 thousand in 2023, a reduction of about 64%[17] - The total assets less current liabilities amounted to RMB 12,963,000 in fiscal year 2024, a significant improvement from a negative net asset position of RMB (316,708,000) in fiscal year 2023[7] - As of June 30, 2024, the company had total assets of approximately RMB 178,200,000 and net assets of approximately RMB 13,000,000[54] Debt and Financing - The company reported a debt restructuring gain of RMB 202,024,000 in fiscal year 2024, which contributed significantly to the overall profit[3] - Financing costs from continuing operations for fiscal year 2024 were approximately RMB 3,200,000, a decrease of about 72.4% from RMB 11,700,000 in fiscal year 2023[52] - The company issued 140,000,000 shares at an issue price of HKD 0.55, raising approximately HKD 77,000,000 (approximately RMB 70,610,000) as part of the creditor plan[51] - As of June 30, 2024, there were no outstanding unsecured corporate bonds, compared to approximately HKD 279,769,000 as of June 30, 2023[58] - The company has not experienced significant foreign exchange or interest rate volatility risks during the fiscal year 2024, and currently has no foreign exchange hedging policies in place[62] Dividends - The company did not recommend any dividend distribution for fiscal year 2024, consistent with fiscal year 2023[1] - The company did not declare or propose any dividends for the year ended June 30, 2024, consistent with the previous year[28] - The company has not proposed any dividends for the fiscal year 2024, consistent with the previous fiscal year[69] Auditor and Governance - The independent auditor's report expressed a qualified opinion regarding the fair value measurement of certain assets, specifically artificial forest assets valued at RMB 48,420,000 and ginseng assets at RMB 22,000,000 as of June 30, 2023[35] - The board and audit committee acknowledged the auditor's qualified opinion and confirmed their agreement with the auditor's findings[37] - The audit committee was established in September 2009, consisting of three independent non-executive directors[76] - The audit committee reviews the company's financial reporting processes and internal control systems before submitting interim and annual reports to the board[76] - The company has adopted all the corporate governance code provisions as per the listing rules and believes it has complied with them during the fiscal year 2024[73] Employee Information - The company has a total of 33 employees and management personnel as of June 30, 2024, an increase from 18 employees in the previous year[65] - The total employee cost for the reporting period is approximately RMB 3,300,000, compared to RMB 5,300,000 in the previous fiscal year[65]